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Abstract
Currently, drug metabolization and toxicity studies rely on the use of primary human hepato-
cytes and hepatoma cell lines, which both have conceivable limitations. Human pluripotent
stem cell (hPSC)—derived hepatocyte-like cells (HLCs) are an alternative and valuable
source of hepatocytes that can overcome these limitations. EZH2 (enhancer of zeste homo-
log 2), a transcriptional repressor of the polycomb repressive complex 2 (PRC2), may play
an important role in hepatocyte development, but its role during in vitro hPSC-HLC differenti-
ation has not yet been assessed. We here demonstrate dynamic regulation of EZH2 during
hepatic differentiation of hPSC. To enhance EZH2 expression, we inducibly overexpressed
EZH2 between d0 and d8, demonstrating a significant improvement in definitive endoderm
formation, and improved generation of HLCs. Despite induction of EZH2 overexpression
until d8, EZH2 transcript and protein levels decreased from d4 onwards, which might be
caused by expression of microRNAs predicted to inhibit EZH2 expression. In conclusion,
our studies demonstrate that EZH2 plays a role in endoderm formation and hepatocyte dif-
ferentiation, but its expression is tightly post-transcriptionally regulated during this process.
Introduction
Currently, primary human hepatocytes (PHHs) are the gold standard for in vitro drug toxicity
and metabolization studies. Use of PHHs is however limited due to scarcity of donors, high
inter-donor variability and rapid in vitro dedifferentiation [1]. Human pluripotent stem cells
(hPSCs) have the capacity to differentiate into the three somatic germ layers and all cell types of
the body, and are an alternative and renewable source of hepatocytes that could be used for
drug toxicity and metabolization studies. hPSC-derived hepatocytes have many advantages over
primary hepatocytes and hepatocellular carcinoma cell lines, as they could provide an unlimited
supply of hepatocytes from a single donor, limiting inter-donor variability; as well as create cells
from a diverse number of patients to study mechanisms underlying drug-induced liver injury
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Although hPSCs can differentiate towards the hepatocyte lineage and exhibit several liver-
specific characteristics (i.e. expression of hepatocyte marker genes, albumin (ALB) secretion,
glycogen storage, urea production; susceptibility to human specific hepatotropic infections,
such as hepatitis virus B, C and E) [2–8], it is not yet possible to create fully mature PHHs
from hPSCs. Indeed, PSC-derived hepatocyte progeny are termed fetal hepatocytes (FH) or
hepatocyte-like cells (HLCs), as the cells continue to express for instance the fetal marker
alpha-fetoprotein (AFP); remain glycolytic, and do not express mature type I & II detoxifica-
tion enzymes [9–14]. Thus, one of the major goals of many groups developing hepatocyte
progeny from hPSCs is to improve the differentiation system to create efficiently and repro-
ducibly fully mature hepatocytes with phenotypic and metabolic similarities with PHHs.
Generation of hepatocytes involves sequential cell fate choices as a result of spatio-temporal
modulation of the chromatin of gene regulatory regions. The histone methyltransferase, Enha-
ncer of Zest Homolog 2 (EZH2), is the catalytic subunit of the polycomb repressive complex 2
(PRC2). Together with other PRC2 subunits (i.e. Embryonic Ectoderm Development (EED)
and SUZ12), EZH2 mediates epigenetic silencing of target genes via trimethylation of histone
H3 lysine residue 27 (H3K27me3) at specific regulatory loci [15–17]. Many of these genes are
related to cell cycle checkpoints and differentiation, suggesting a major role of EZH2 in pro-
moting cell proliferation and self-renewal [18,19]. Indeed, deletion of EZH2 in hPSC leads to
compromised self-renewal and differentiation defects [20]. PRC2 is not necessary for maintain-
ing ESC self-renewal, as each of the PRC2 components can be deleted without compromising
the expression levels of pluripotent markers, such as OCT4 and NANOG [21,22]. Moreover,
ESC lacking SUZ12, EED or EZH2 show aberrant de-repression of lineage-specific genes and
are unable to properly differentiate. This is also partially due to the lack of repression of pluripo-
tent genes during differentiation [21,22]. It has also been described that in hepatic stem/progen-
itor cells EZH2 has the capacity to block the differentiation towards hepatocytes [23], however
we have shown that inhibition of EZH2, at a later time point of hepatocyte differentiation, de-
creased H3K27me3 in regulatory regions, but did not affect hepatocyte gene expression, and is
therefore dispensable for the later stages of maturation of hESCs to a mature hepatocyte pheno-
type in vitro [24]. This suggests that temporary overexpression of EZH2 during the initial steps
of the PSC-hepatocyte differentiation protocol, but not at later stages should improve the gener-
ation of mature hepatocytes from PSCs.
Here, we demonstrate that doxycycline inducible overexpression of EZH2 from the AAVS1
locus resulted in improved definitive endoderm formation from hPSCs and subsequent fetal
hepatocytes generation. Surprisingly, despite doxycycline mediated EZH2 overexpression
between endoderm and hepatoblast stage of the differentiation protocol, transcript and protein
levels of EZH2 decreased progressively from endoderm onwards. This was associated with an
increased expression of micro (mi)RNAs that are known/predicted to suppress EZH2 expres-
sion. In conclusion, we demonstrate that EZH2 plays an important role in hepatocyte differen-
tiation and that its expression is tightly post-transcriptionally regulated.
Materials and methods
Cell lines and hESC differentiation to the hepatocyte lineage
The human embryonic kidney (HEK293) cell line was cultured in Dulbecco’s Modified Eag-
les’s Medium (DMEM, Invitrogen, USA) medium that contained 10% fetal bovine serum
(FBS) and 1X penicillin/streptomycin (Invitrogen, USA). The hESC H9 line (WAO9, WiCell)
was cultured on inactivated mouse embryonic fibroblasts (iMEF) as described [25].
EZH2 dynamics in hepatocyte-like cell
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Experiments were performed with approval from the Medical Ethics Committee (UZ Leuven,
Gasthuisberg). Hepatocyte differentiation was done as described earlier with minor modifica-
tions [5,7,24,26]. EZH2 was induced in the cultures by administration of 5μg/ml doxycycline
(Sigma-Aldrich) from day 0 to day 4 and day 8 by changing media completely every 2 days. All
growth factors were purchased from PeproTech.
Plasmid construct and generation of the master cell lines and
Recombinase-Mediated Cassette 3xchange (RMCE) line
All constructs were fully sequenced before use. EZH2 transcript variant 1 (TV1) fused to a myc
epitope was obtained by RT-PCR from hESCS and was cloned into the pZ:F3-P P TetOn-F [26]
vector which contains the Tetracycline Response Element (TRE) from pTRIPZ (Open Biosys-
tems). The “all-in-one” vector contains the TRE driving the expression of Myc-EZH2 in reverse
orientation to the CAGGS m2rtTA cassette. The master cell line and the RMCE line were gen-
erated as described [26]. EZH2 transcript variant 1 (TV1) was cloned into pLVX-IRES-Hygro
(Clontech) vector and used as positive control.
Immunofluorescence and flow cytometry
hESCS and/or differentiated cells were grown on glass slides and fixed with 4% paraformaldehyde
(PFA), permeabilized with 0.2% Triton X-100 in PBS, blocked with 5% normal donkey serum
(Jackson Laboratory), and stained overnight at 4˚C with OCT4 (0.4 μg/mL, Santa Cruz Sc-8628),
TRA-1-60 (1 μg/ml, Millipore-Chemicon MAB4360), SOX17 (5 μg/mL, R&D AF1924), HNF4A
(5 μg/mL, Abcam Ab41898), ALB (2.5 μg/mL, Dako A0001) and AAT (3.95 μg/mL, Dako A0012),
or the relevant isotype controls in Dako diluent (Dako). Secondary antibodies were used at 1:500
dilution (species-specific AF555-conjugated immunoglobulin G, Alexa Fluor, Molecular Probes)
and nuclei were visualized using Hoechst (Sigma-Aldrich). Signals were detected with an Axioima-
ger.Z1 microscope and analyzed with the Axiovision software (Zeiss). The percentage of SOX17
and HNF4α positive cells was manually counted on five representative 10× images. For all pictures,
the percentage of positive cells was contoured above the isotype level and three different differenti-
ations were averaged. The histone modification H3K27me3 was stained and quantified as descri-
bed [24]. For CXCR4/cKIT flow cytometry, cells were detached at day 4 with trypsin 0.05% and
stained with 1μg/mL anti-CXCR4-PE and 2μg/ml anti-cKIT-APC antibody for 15 minutes at
room temperature. Afterwards cells were washed and analyzed by flow cytometry analysis using a
FACS-Canto (BD).
For intracellular AAT flow cytometry staining, a single cell suspension was made by liberase
treatment (Roche) followed by fixation with 4% PFA. Next, cells were permeabilized with 0.1%
saponin and blocked with 10% goat serum (Dako). Afterwards cells were stained with 0.0625μg/
200μL/10^6 cells anti-AAT antibody (Dako) or a rabbit IgG isotype control (BD Pharmingen)
for 1h at RT. A secondary Alexa Fluor 647 antibody (1:1500) (Invitrogen) was used for 30 min-
utes at RT. Cells were analyzed by flow cytometry analysis using a FACS-Canto (BD) and ana-
lyzed with FACS Diva Software (BD Biosciences).
RNA extraction and quantitative reverse-transcription PCR (qRT-PCR)
For gene expression analysis, RNA was isolated from differentiated progeny cells by the GenElute
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) following manufacturer’s procedures.
Genomic DNA was eliminated using the On-Column DNase I Digestion kit (Sigma-Aldrich).
The Superscript III First-Strand synthesis system (Invitrogen) was used for subsequent cDNA
synthesis. qPCR was performed with the Platinum SYBR green qPCR supermix-UDG kit (Invi-
trogen) in a ViiA 7 Real-Time PCR instrument (Thermo Fisher Scientific, Waltham, MA).
EZH2 dynamics in hepatocyte-like cell
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene for
normalization. Sequences of qRT-PCR primers are listed in Table 1. Relative expression to
GAPDH was calculated as 2-ΔCt and relative gene expression as fold change was calculated as 2-
ΔΔCt.
microRNA (miRNA) analysis
Total RNA samples, which include RNA from approximately 18 nucleotides (nt), were
extracted and purified using miRNeasy Mini Kit (QIAGEN, ID: 217004) accordingly to the
manufacturer’s procedures.
Then, 1μg of RNA was polyadenylated and reverse transcribed (RT) using NCodeTM
miRNA First-Strand cDNA Synthesis and qRT-PCR Kit (Invitrogen, MIRQ-10) with a univer-
sal primer. For the quantification miRNAs, real-time PCR for each microRNA assay was car-
ried out in 10μl reaction mixture included 2 μl of diluted RT product, 2× SYBR green, and
0.5 μM forward primer and reverse primer. The reaction was incubated in ViiA 7 Real-Time
PCR instrument (Thermo Fisher Scientific, Waltham, MA) in 384-well plates at 95˚C for 10
min, followed by 45 cycles of 95˚C for 15 sec and 60˚C for 30 sec. U6 was used as the house-
keeping gene for normalization. Sequences of miRNA primers are listed in Table 2. Relative
expression to U6 was calculated as 2-ΔCt and relative gene expression as fold change was cal-
culated as 2-ΔΔCt.
Protein extracts, immunoblotting, and antibodies
For protein expression analysis, cells from differentiated progeny cells were lysed in 2x Laemmli
Buffer (100 mM Tris-Cl (pH 6.8), 2% SDS, 20% glycerol and 4% β-mercaptoethanol added
fresh) in PBS at 95˚C for 10 min. Protein extracts were separated using a SDS-PAGE gel and
transferred onto a nitrocellulose membrane (Whatman International Ltd, Maidstone, UK).
Immunoblots were incubated with primary antibodies against EZH2 (Purified Mouse, BD dil.
1:100), RING1B (dilution 1:1000, Santa Cruz Biotech sc-101109), GATA4 (dilution 1:400, Santa
Cruz Biotech sc-25310) and GAPDH (dilution 1:2000, Santa Cruz Biotech sc-47724) as loading
control. Subsequently, HRP conjugated secondary antibodies against rabbit and mouse IgG
were procured from Jackson Immunologicals (West Grove, PA). Immuno-reactive bands were
then visualized using Super Signal1 West Pico chemi-luminescent substrate (Thermo Scien-
tific, Rockford, IL).
Chromatin immunoprecipitation (ChIP)
ChIP was performed using 1x10^6 cells per H3K27me3 histone modifications. IPs were processed
as described before [27]. Dynabeads (Life Technologies) were added and DNA purified using
QIAquick PCR purification kit (Qiagen). Purified DNA was analyzed by qPCR. ChIP-grade ABs
used, ChIP-qPCR data analysis and primers sequences for GAPDH, MYOD1, HOXD11, ALBU-
MIN and AAT are described in [24]. SOX17 5’-AGGTCACCCACCACTGAAAC-3’and 5’-GA
ACATACCGAGCGTCCATT-3’,FOXA2 (5’-AATCTGGGCTCACAGGCTAA-3’ and 5’-TGTC
TTCCAGAGGGACTGCT-3’)and CXCR4 5’- TCCAGACCTGGGAATGCTAC-3’and 5’- GTT
GGAAGCTTGGCCCTACT-3’.
Albumin ELISA
Enzyme-linked immunosorbent assay (ELISA) for ALBUMIN was performed according to the
manufacturer’s procedure (Bethyl, Montgomery, TX). Briefly, at day 16 of the hepatocyte dif-
ferentiation protocol, supernatant was collected and incubated as described in [5].
EZH2 dynamics in hepatocyte-like cell
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Table 1. Gene expression primers.
Gene Forward Reverse
GAPDH TCAAGAAGGTGGTGAAGCAGG ACCAGGAAATGAGCTTGACAAA
EZH2 TGGGAAAGTACACGGGGATA CAGGATCGTCTCCATCATCA
EZH2 total TGATGCCCTGAAGTATGTCG GGGTTCCTTCCGGTATTGTC
EZH1 TTTTCATGCCACCCCTAATG AGCATGGCATACTCCTTTGC
SUZ12 AAACGAAATCGTGAGGATGG CCATTTCCTGCATGGCTACT
EED GGCAATATTTGGAGGCGTAG GAATGATCCATACCACAGGACA
RING1B GTGCAGACAAACGGAACTCA TCGAGGTGAAACCACAATTTC
BMI1 TGTTCGTTACCTGGAGACCA TTTTGAAAAGCCCTGGAACT
OCT4 TCGAGAAGGATGTGGTCCGA GCCTCAAAATCCTCTCGTTG
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT
FOXA2 AGGAGGAAAACGGGAAAGAA GGTGCTTGAAGAAGCAGGAG
EOMES AACAACACCCAGATGATAGTC TCATAGTTGTCTCTGAAGCCT
MIXL1 GGATCCAGGTATGGTTCCAG CATGAGTCCAGCTTTGAACC
GOOSECOID TCTCAACCAGCTGCACTGTC CCAGACCTCCACTTTCTCCTC
BRACHYURY ACCCAGTTCATAGCGGTGAC AAGCTTTTGCAAATGGATTG
SOX17 CGCTTTCATGGTGTGGGCTAAGGACG TAGTTGGGGTGGTCCTGCATGTGCTG
CXCR4 CACCGCATCTGGAGAACCA GCCCATTTCCTCGGTGTAGTT
HNF4A ACTACGGTGCCTCGAGCTGT GGCACTGGTTCCTCTTGTCT
HNF1A ACACCTCAACAAGGGCACTC TGGTAGCTCATCACCTGTGG
HNF3B AGGAGGAAAACGGGAAAGAA GGTGCTTGAAGAAGCAGGAG
HNF3G ATTCTCTCTGGCATGGGTTG AAATTCCCCACACCCTAACC
HNF6 AAATCACCATTTCCCAGCAG ACTCCTCCTTCTTGCGTTCA
GSTA1 TCTGCCCGTATGTCCACCT GCTCCTCGACGTAGTAGAGAAGT
APOA1 TGGATGTGCTCAAAGACAGC TCACCTCCTCCAGATCCTTG
SRBI TGAACTGCTCTGTGAAACTG AATAGCATTTCTCTTGGCTCC
GSTp CCCTACACCGTGGTCTATTTCC GAGGCTTTGAGTGAGCCCT
AFP TGAGCACTGTTGCAGAGGAG GTGGTCAGTTTGCAGCATTC
PROX1 TCACCTTATTCGGGAAGTGC GGAGCTGGGATAACGGGTA
ALBUMIN ATGCTGAGGCAAAGGATGTC AGCAGCAGCACGACAGAGTA
AAT AGGGCCTGAAGCTAGTGGAT TCCTCGGTGTCCTTGACTTC
MRP2 CGATATACCAATCCAAGCCTC GAATTGTCACCCTGTAAGAGTG
NTCP ATCGTCCTCAAATCCAAACG CCACATTGATGGCAGAGAGA
PEPCK AAGAAGTGCTTTGCTCTCAG CCTTAAATGACCTTGTGCGT
CKIT TCAGTGCATAACAGCCTAATCTC GTTCTGCTCCTACTGCTTCG
PXR TTCCGGGTGATCTCGCA ACTGGCTATCACTTCAATGTCA
CAR GCTCCTGCTGTGCTTCGT GCATGGCAGATAGGCAGTTT
P300 CCAGATGGGAGGACAAACAG CCAATCTGCTGTCCAGGATT
CEBPA AAAGGGGTGGAAACATAGGG GGAGAGGCGTGGAACTAGAG
CEBPB CAACAAGCCCGTAGGAACAT ATTCTCTCTGGCATGGGTTG
PDX1 TCCACCTTGGGACCTGTTTA GTGTGTTAGGGAGCCTTCCA
NEUROD1 CTCGGACTTTTCTGCCTGAG GTGGAAGACATGGGAGCTGT
NGN3 TCTCTATTCTTTTGCGCCGG CTTGGACAGTGGGCGCAC
NKX6.1 CCATCTTCTGGCCCGGAGTGA CTTCCCGTCTTTGTCCAACAA
PAX6 CCCAAGAGCAAATTGAGGCCC CTCTTCTCCATTTGGCCCTTCGA
INK4A GAAGGTCCCTCAGACATCCCC CCCTGTAGGACCTTCGGTGAC
INK4B ACTAGTGGAGAAGGTGCGAC GCCCATCATCATGACCTGGA
ARF CCCTCGTGCTGATGCTACTG ACCTGGTCTTCTAGGAAGCGG
(Continued )
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DNA methylation by bisulfite sequencing
Genomic DNA of the cells was extracted using the QIAamp DNA Mini kit (QIAGEN) and
500ng DNA were used to perform the bisulfite conversion with EpiTect Bisulfite Kit (QIA-
GEN), according to the manufacturer’s instructions and the following cycling process: [95˚C,
30 sec– 50˚C, 1 hour] X16–10˚C as previously described [28]. Regular PCR was used to
amplify specific fragments using 10-20 ng of converted DNA using forward 5’-TTGTATTT-
TAGTTTGGATAATTAGAG-3’and reverse 5’-AAAAACCAAATTTAAACCAATTCAA-3’
primers. The PCR products were cloned into a p-GEM easy vector (Promega) and 15-20
clones were sequenced. The methylation rate of the CpG pairs was quantified using QUMA
software.
Results
The expression of EZH2 decreases during hepatocyte differentiation
We first evaluated the transcript levels of the polycomb group (PcG) genes EZH2, EZH1,
SUZ12, EED, RING1B and BMI1 in hPSCs, definitive endoderm (endo_d4), hepatic progeni-
tors (HP_d8) and fetal hepatocytes (FH_d16) derived from hPSCs (Fig 1A, upper part)
[5,7,24,26]. An intermediate point, hPSC-derived hepatoblast at day 12, has not been analyzed
in this manuscript. EZH1, SUZ12 and EED were expressed at constant levels throughout the
hepatocyte differentiation protocol, whereas transcript levels for RING1B decreased and BMI
increased by day 16 (S1 Fig). Expression of EZH2 was gradually decreasing during the progres-
sion of the hepatocyte differentiation protocol (day 4, endo and day 8, HP), and significantly
decreased by day 16, FH (Fig 1A, bottom part and S1 Fig). Different from the RT-qPCR results
Table 1. (Continued)
Gene Forward Reverse
P21 GGCAGACCAGCATGACAGATTTC CGGATTAGGGCTTCCTCTTGG
CYP1A2 CAGCTCTGGGTCATGGTTG CCTCCTTCTTGCCCTTCAC
CYP2C9 GTTTCTGCCAATCACACGTTC CTGCAGTTGACTTGTTTGGAG
CYP2A6 GTTGTACATCTGCTCTGTGTTC GTGGCCTTGCTGGTCTG
CYP3A7 CTCCCTGAAAGGTTCAGTAAA AAGAAGTCCTCCAAAGCG
https://doi.org/10.1371/journal.pone.0186884.t001
Table 2. miRNAs expression primers.
Mature name Primer
hsa-miR-101-3p CCGGTACAGTACTGTGATAACTGAA
hsa-miR-138-5p AGCTGGTGTTGTGAATCAGGC
hsa-miR-214-3p TGCCTGTCTACACTTGCTG
hsa -miR-124-5p CGTGTTCACAGCGGACCTTG
hsa -miR-31-5p AGGCAAGATGCTGGCATAGC
hsa -miR-98-5p GAGGTAGTAAGTTGTATTGT
hsa-miRNA-125b-5p TCCCTGAGACCCTAACTTG
has-miR-139-5p TACAGTGCACGTGTCTCCAGT
hsa-miRNA-181a-5p AACATTCAACGCTGTCGGTG
hsa-miR-181b-5p AACATTCATTGCTGTCGGTGG
has-miRNA-200b-3p TAATACTGCCTGGTAATGAT
has-miR-217 TACTGCATCAGGAACTGATTGG
U6 CTCGCTTCGGCAGCACA
https://doi.org/10.1371/journal.pone.0186884.t002
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(Fig 1A, bottom part and S1 Fig), no changes in RING1B protein levels were observed by west-
ern blot throughout differentiation (Fig 1B). However, western blot analysis for EZH2 protein
during hepatocyte differentiation demonstrated an increase in EZH2 between day 0 and day 4
of differentiation, and a decrease of EZH2 from day 8 to day 16 of differentiation (Fig 1B). The
low levels of EZH2 protein in undifferentiated hPSCs were not in accordance with the tran-
script levels detected by RT-qPCR (Fig 1A, bottom part). Thus, during HLCs generation from
PSCs, there appears to be a dynamic regulation of EZH2 protein.
To investigate whether epigenetic modifications modulate EZH2 gene expression during
hPSC-HLCs differentiation, we studied the role of DNA methylation of the regulatory region
upstream of the transcription start site (TSS) of EZH2, containing 33 CpG sites in a CpG island
(Fig 1C, upper part), in hPSCs, HP (day 8) and FH (day 16). Bisulfite sequencing demonstrated
DNA hypomethylation of this region at all 3 steps of differentiation analyzed (Fig 1C, bottom
part). These results indicate that expression levels of EZH2 are not regulated by DNA methyla-
tion in the region of the TSS of EZH2, but suggest that EZH2 mRNA could be regulated by
other epigenetic modifications, as the protein levels are most likely regulated by posttransla-
tional modifications.
Definitive endoderm (DE) formation is improved by EZH2
overexpression
We recently described an efficient and very fast method to introduce doxycycline (doxy)
inducible transgenes in hPSCs, by recombinase mediated cassette exchange (RMCE) in a flip-
pase recognition target (FRT) flanked cassette in the adeno-associated virus integration site-1
(AAVS1) locus of hPSCs [26]. This allowed us to study the effect of inducible EZH2
Fig 1. EZH2 expression during hepatocyte differentiation. A. Upper part, differentiation protocol of hPSCs into hepatocytes-like cells. hESC were
harvested and plated at ±7 x 104 cell/cm2 and differentiated with a combination of growth factors: 50ng/ml of Activin-A and Wnt3a for the first 2 days and
50ng/ml Activin-A until day 4, followed by BMP4 50 ng/ml from day 4 until day 8, FGF1 50 ng/ml from day 8 until day 12, and HGF 20 ng/ml from day 12
until day 16. Differentiated progeny of the hESC line were harvested on day 4 (endo_d4, definitive endoderm cells), on day 8 (HP_d8, hepatoblast
progenitor) and on day 16 (FH_d16, fetal hepatocyte). Bottom part, transcript expression levels of EZH2 and RING1B in hPSCs, endo, HP and FH
stages. GAPDH was used as a control. Data as mean ± SEM of n 3 IEs. *** p < 0.001 by Student’s t test. B. Western blot analysis of EZH2, RING1B
and GAPDH on hPSCs, endo, HP and FH stages. GAPDH was used as loading control. HEK293T transiently transfected with pLVX-IRES-Hygro-
hEZH2 cells were used as positive control. Signals were quantified and indicated as % to loading control. C. Schematic representation of the EZH2
regulatory region. Approximately 270bp (arrow in front of the TTS) in a CpG island were bisulfite sequenced in undifferentiated hPSC, HP and FH.
Percentages of the results of bisulfite sequencing of the regions are at right side of the figure for each stage.
https://doi.org/10.1371/journal.pone.0186884.g001
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overexpression on the differentiation potential of hPSCs towards HLCs. We inserted the
amplified, human EZH2 transcript variant 1 (hEZH2 tv1, NM_004456) sequence into the “all-
in-one” inducible RMCE donor vector that contains the tetracycline response element (TRE)
driving the expression of the transgene in reverse orientation to the CAGGS m2rtTA cassette
(Fig 2A) and flanked by FRT sites. The cassette was introduced by flippase-mediated cassette
exchange in the AAVS1 as described earlier [26]. The ihEZH2 inducible cell line (hPS-iEZH2)
maintained the typical pluripotency characteristics of hPSCs as the expression of pluripotency
genes OCT4 and TRA1-60 was comparable to wild-type hPSCs (Fig 2B).
To further investigate the regulatory role of EZH2 during hPSC differentiation into defini-
tive endoderm (endo_d4) we induced the expression of EZH2 with doxy from day 0 to day 4
in hepatocytes differentiation protocol (Fig 1A, upper part). Both western blot (Fig 2C) and
RT-qPCR (Figs 3A, bottom part and 5A) analysis confirmed that addition of 5μg/ml doxy to
the differentiation medium from day 0 to day 4 significantly induced the expression of EZH2
compared to the untreated control. In response to the higher levels of EZH2, a significantly
more homogenous population of definitive endoderm cells was generated on day 4, demon-
strated by flow cytometry analysis for CXCR4/cKIT double positive cells (75.2±0.91% in the
presence of doxy and 53.9±3.29% in the absence of doxy, n = 3, p = 0.0172) (Fig 2D). This
coincided with a significant increase in SOX17 positive cells (57.94±4.31% with doxy vs. 27.64
±4.32% without doxy, n = 2, p = 0.00009), demonstrated by immunostaining (Fig 2E) and also
by RT-qPCR (Fig 2F). In addition, transcripts for the definitive endoderm markers, FOXA2,
EOMES, MIXL1, GOOSECOID and CXCR4, were up regulated in doxy-treated (Fig 2G) com-
pared to untreated control cells. As expected, 8 days post differentiation (HP_d8), expression
of the definitive endoderm markers FOXA2, EOMES, MIXL1, GOOSECOID and CXCR4
decreased, and no differences were seen between doxy-treated or untreated cells (Fig 2G). RT-
qPCR also demonstrated that the key pluripotency markers OCT4 and NANOG decreased
over-time (S2 Fig). In conclusion, EZH2 induction significantly improved definitive endo-
derm formation.
Regulation of EZH2 overexpression during hepatocyte differentiation
To address if induction of EZH2 also improved the generation of day 16 fetal hepatocytes from
hPSCs, we differentiated hPS-iEZH2 with or without 5μg/ml doxycycline (doxy) from the start
of differentiation until day 8 (Fig 3A, upper part). EZH2 was significantly induced in hPSC-
progeny on day 4. Despite continued addition of doxy until day 8, EZH2 mRNA levels were
almost zero beyond day 4, as analyzed by RT-qPCR with primers selective for the EZH2 variant
1 transgene transcript (Exogenous EZH2, Fig 3A, left) and primers that recognized both
endogenous and transgenic EZH2 mRNA (Total EZH2, Fig 3A right). Expression of EZH1
mRNA did not change throughout differentiation and was not affected by doxy treatment (S2
Fig). Western blot confirmed that EZH2 protein levels were higher in doxy treated compared
with control cells on day 4, but were no longer higher on day 8, and were not detectable on day
16 (Fig 3B). Thus, despite addition of doxy between day 0 and day 8, EZH2 transcript and pro-
tein levels decreased progressively from day 4 onwards, suggesting that post-transcriptional
regulation of EZH2 during differentiation might be responsible for EZH2 mRNA down-
regulation.
We also examined the effect of EZH2 overexpression on the differentiation of hPSCs
towards fetal hepatocytes on day 16. Although EZH2 transcripts and protein were only
enhanced during the initial 4 days of differentiation, we observed a significant increased
expression of HNF3B and GSTp on day 8, and a significant increase in HNF1A, HNF3B,
CEBPA, and CAR transcripts on day 16 (Fig 3C). We also found significantly increased
EZH2 dynamics in hepatocyte-like cell
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transcript levels for ALB and AAT, two genes expressed in mature hepatocytes (Fig 3D). AFP, a
typical hepatoblast/fetal hepatocyte gene, is continuously expressed as expected for the fetal
nature of the hPSC-derived hepatocytes among samples (Fig 3D). We also monitored the
expression of some additional fetal markers (CYP3A7,CYP1A2 and CKIT) and mature hepato-
cyte genes on day 8 and day 16 (CYP2A6,CYP2C9,CEBPB, GSTA1, APOA1, NTCP, SRBI,
P300,MRP2, PROX1, PEPCK, PXR and HNF3G). Only the levels of CYP3A7,CYP2A6 and
CYP2C9were significantly influenced by overexpression of EZH2 between day 0 and day 4 (S3
Fig).
On HP_d8, levels of HNF4AmRNA were not affected by addition of doxy (Fig 3E, left), but
immunostaining demonstrated presence of significantly more HNF4A positive cells in the
doxy treated cells (83.5±3.37% with doxy vs. 53.3±7.58% without doxy, n = 3, p = 0.0409) (Fig
3E, right). On HP_d8 and FH_d16, immunostaining (Fig 3F and 3H) suggested that more
doxy-treated progeny stained positive for ALBUMIN and AAT (n = 2). Consistently, ALBU-
MIN secretion by doxy treated progeny was significantly increased on day 16 (Fig 3G), and
flow cytometry analysis demonstrated that significantly more doxy treated cells stained posi-
tive for AAT (60.9 ±8.51% with doxy vs. 27.7 ±2.31 without doxy, n = 4, p = 0.015).
As EZH2 also plays a role in pancreas versus liver fate choice from endoderm [29,30],
we also assessed the expression of PDX1, NGN3, NEUROD1, NKX6.1 and PAX6 during
differentiation. We did not observe increased levels of these transcripts (S3 Fig) on day 8
and day 16 hPSC progeny in the presence of doxy compared with cultures without doxy,
indicating that the improved hepatocyte specification as a result of EZH2 induction was
specific.
Thus, enhanced expression of EZH2 between day 0 and day 4 significantly increased
ALBUMIN secretion and significantly increased AAT expressing cells on d16 of differentia-
tion, while not affecting pancreatic fate commitment. Interestingly, improved hepatic commit-
ment on day 16 occurred despite the fact that EZH2 transcript and protein levels were only
significantly elevated between day 0 and day 4.
Upon doxy-mediated induction of EZH2, H3K27me3 was significantly increased on day 4,
day 8 and d16 hPSC progeny cells as was shown in Fig 4A (by immunofluorescence, left, and
by densitometric analysis, right), while H3K27me3 significantly decreased on the endodermal
markers (Fig 4B, left). The level of H3K27me3 on GAPDH, MYOD1 and HOXD11 remained
unchanged between treated and doxy-treated cells on day 4 (Fig 4B, right). Moreover, a signifi-
cant reduction of H3K27me3 on ALBUMIN (Fig 4C, left) and an increase on HOXD11 on day
16 (Fig 4C, right), a typical EZH2 target gene, suggested that EZH2 induction probably leads
to the repression of not-hepatocyte genes while inducing endodermal and hepatocyte genes.
Fig 2. hESC-inducible EZH2 (hPSC- iEZH2) cell line and definitive endoderm formation. A. The original master cell line flanked by heterotypic
FRT sequences and resulting RMCE line (Recombinase-Mediated Cassette Exchange, hPSC-iEZH2) are depicted. RMCE donor vector pZ:F3-P
TetOn hEZH2 for inducible expression was introduced by flippase (additional details in the Supplemental Information). B. Expression of pluripotency
markers (TRA-1-60 and OCT4) of a representative hPSC-iEZH2 clone and wild-type hPSCs by immunocytochemistry. Right: isotype control of TRA-1-
60 and OCT4. C. Upper part, directed differentiation of hPCS-iEZH2 toward endoderm (endo_d4) with addition of 5μg/ml doxycycline (doxy) in the first 4
days of differentiation (red arrow). Bottom part, protein analysis of untreated and doxy treated EZH2 induced cells (doxy -/+) using EZH2, GATA4 and
GAPDH antibodies. GAPDH was used as loading control. Signals were quantified and indicated as % to loading control. D. Double extracellular staining
for CXCR4 (PE channel) and cKIT (APC channel) measured by FACS in untreated and doxy treated EZH2 induced cells (doxy-treated) at definitive
endoderm stage on day 4. Right: the percentage of cells co-expressing CXCR4 and cKIT. Data as mean ±SEM of n 3 IEs. ** p < 0.01 by Student’s t
test. E. Representative immunofluorescence images for SOX17 (red signal) in untreated and EZH2 induced cells (doxy-treated) at day 4 of differentiation.
EZH2 induced cells showed significantly high levels of SOX17 expression. Around 58% of positive cells were counted in EZH2 doxy induced cells, right
part. Nuclei are staining with DAPI (blue). Data as mean ± SEM of n 3 IEs. *** p < 0.001 by Student’s t test. F. mRNA expression profile of the
endoderm marker SOX17 in untreated (-) and EZH2 doxy induced cells (+) at endo_d4. G. mRNA expression profile of untreated (-) and EZH2 doxy
induced cells (+) at endo_d4 and HP_d8 of endoderm markers FOXA2, EOMES, MIXL1, GOOSECOID and CXCR4. Relative gene expression to
GAPDH. Data as mean ± SEM of n 3 IEs.
https://doi.org/10.1371/journal.pone.0186884.g002
EZH2 dynamics in hepatocyte-like cell
PLOS ONE | https://doi.org/10.1371/journal.pone.0186884 November 1, 2017 10 / 19
Fig 3. EZH2 regulation and fetal hepatocytes differentiation. A. Upper part, directed differentiation of hPCS-iEZH2 toward fetal hepatocytes (FH_d16)
with addition of 5μg/ml doxycycline (doxy) in the first 8 days of differentiation (red arrow). Bottom part, relative gene expression of the EZH2 transgene
(Exogenous EZH2) and both endogenous and exogenous EZH2 (Total EZH2) at endo_d4, HP_d8 and FH_d16 in untreated (-) and EZH2 doxy induced cells
(+). Relative gene expression to GAPDH and same scale bar. Data as mean ± SEM of n 3 IEs. B. Western blot for EZH2 and GAPDH in untreated (-) and
EZH2 doxy induced cells (+) at hPSC, endo_d4, HP_d8 and FH_d16. Positive control: HEK293T cells transiently transfected with pLVX-IRES-Hygro-
hEZH2. The molecular weight size marker was cropped from the gel. Signals were quantified and indicated as % to loading control. C. Relative expression
(to GAPDH) of hepatic markers HNF1A, HNF3B, HNF6, GSTp and transcription factors CAR and CEBPA in HP_d8 and FH_d16 untreated (-) and EZH2 doxy
induced cells (+). Data as mean ±SEM of n 3 IEs. * p < 0.05 and ** p < 0.01. D. Relative gene expression (to GAPDH) of hepatic marker genes AFP,
ALBUMIN and AAT in HP_d8 and FH_d16 untreated (-) and EZH2 doxy induced cells (+). Data as mean ± SEM of n 3 IEs. * p < 0.05, ** p < 0.01. E. Left
part, relative gene expression (to GAPDH) of hepatic transcription factor HNF4A in HP_d8 and FH_d16 untreated (-) and EZH2 doxy induced cells (+). Right
part, representative immunofluorescence images for HNF4A (red signal) on day 8 for cells treated without (untreated) or with doxy (doxy-treated). Nuclei are
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Are miRNAs responsible for EZH2 mRNA degradation?
We have previously shown that inducible transgenes remained stably expressed throughout
the differentiation when induction started from day 0 [26]. To further understand the kinetics
of the decreased EZH2 expression from day 4 onwards despite constant administration of
doxy until day 8 (Fig 5A, right), we monitored EZH2 transcript levels daily between day 4 and
day 8. We demonstrated that EZH2 mRNA levels in doxy-treated cells gradually decreased
between day 4 and day 8 (Fig 5A, left) while levels in untreated cells remained constant, sug-
gesting some kind of post-transcriptional regulation mechanism that limited the total amount
of EZH2. We therefore examined the levels of miRNAs known/predicted to have a link to
EZH2 (see Fig 5C). miR-101 has been identified to directly target EZH2, acting as an EZH2
silencer involved in a negative feedback circuit with EZH2 [31,32]. In addition, miR-138 was
recently reported to directly target EZH2 [33] and miR-214 has been shown to directly target
EZH2 during myogenesis [34]. To identify additional candidate miRNAs that might target
EZH2, we used data from published studies [35,36] and examined the online database miRDB
(http://mirdb.org/miRDB/) for miRNA target prediction (S4 Fig). We monitored expression
of 12 know/predicted miRNAs targeting EZH2. As shown in Fig 5B and S4B Fig, expression
levels of all miRNAs analyzed were lower in day 4 hPSCs progeny (±doxy) compared with
undifferentiated hPSCs. Transcript levels of miR-101, miR-138, miR-214 and miR-124 were
significantly higher in day 16 progeny compared to day 8 progeny, which was more pro-
nounced (albeit not significant) for cultures supplemented with doxy (Fig 5B). The other can-
didate EZH2 binding miRNAs displayed a very similar pattern of expression: for example, the
expression kinetics of miR-139 was similar to that of miR-101, and the expression pattern of
miR-31 and miR-200b was comparable to that of miR-138 throughout differentiation (S4 Fig).
miR-98, miR-125 and 181a were detectable only on day 16, and levels were similar between
doxy treated and untreated cells. miR-217 was the only EZH2 binding miRNA that could not
be detected at any point during differentiation (S4 Fig).
These studies demonstrated that miRNAs known/predicted to interact with EZH2 are
highly up regulated during HLC differentiation and might explain a possible mechanisms for
the loss of EZH2 mRNA and EZH2 protein expression from day 4 onwards, despite the trans-
genic overexpression of EZH2 until day 8 of differentiation.
Discussion
hPSCs can differentiate into all somatic cell types of the human body, including hepatocytes.
Thus, hPSC-derived hepatocytes are an attractive alternative to PHHs to test the safety, effi-
cacy, and metabolization of new chemical entities. To date, most hPSC differentiation proto-
cols yield hepatocyte-like cells with phenotypic characteristics of fetal rather than mature
hepatocytes [4,9,10,14,18,24,37,38].
It is well known that regulation of gene expression is modulated by epigenetic modification
caused by DNA methylation, histone modifications and miRNAs. DNA and chromatin modu-
lation in both non-coding and coding regions, tightly regulate gene expression in hPSCs and
staining with DAPI (blue). On the right, more than 80% of HNF4A positive cells on HP_d8 EZH2 doxy induced cells were counted. Data as mean ± SEM of
n 3 IEs. * p < 0.05. F. Immunofluorescence staining for ALBUMIN (red signal) at HP (day8) and FH (d16) in untreated (-) and EZH2 induced cells (+) (left
part). Nuclei are staining with DAPI (blue). Data as representative images of n = 2 IES. G. ELISA for ALBUMIN secretion on FH_d16 of the hepatocyte
differentiation protocol. EZH2 doxy induced cells (+) secrete significant amounts of albumin compared to untreated (-) cells. Data as mean ± SEM of n 3 IEs.
** p < 0.01. H. Immunofluorescence staining for AAT (red signal) at HP (day 8) and FH (day 16) showed abundant expression of the hepatocyte protein in
doxy-treated cells compared to the untreated (left part). Nuclei are stained with DAPI (blue). Data as representative images of n = 2 IES. I. Intracellular flow
cytometry analysis for AAT demonstrated that more then around 60% of EZH2 doxy induced cells (+) progeny were positive for AAT. Results represent the
mean of three independent experiments ± SEM. ** p < 0.01.
https://doi.org/10.1371/journal.pone.0186884.g003
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their progeny. Polycomb complexes in part modulate chromatin structure during lineage com-
mitment [39,40]. EZH2, a core component of PRC2, represses the expression of genes by func-
tioning as a methyltransferase for H3K27me3 [41–43]. We previously published that persistent
H3K27me3 marking of regulatory gene regions of hepatocyte genes is detected during hepato-
cyte differentiation from hPSCs, and this despite increased gene transcription. H3K27me3
marking might therefore not have a determinant role in gene activity in later stages of hepato-
cyte differentiation [24]. It might be possible that hPSC display a distinct histone modification
state on regulatory elements at initial stages, a sort of chromatin “pre-pattern” that may reflect
Fig 4. Total H3 levels and H3K27me3 levels on endodermal and hepatocyte genes. A. Left, representative immunofluorescence
image for H3K27me3 (green signal) of three different differentiations (n = 1, 2 and 3) at endo_d4, HP_d8 and FH_d16 stages in untreated
and doxy-treated cells. Right, the fluorescence of H3K27me3 signal was digitally quantified (additional details in the Supplemental
Information). Results represent the mean of three independent experiments ±SEM and displayed as arbitrary units (A.U.). ** p < 0.01. B.
Histone modification levels of H3K27me3 at SOX17, CXCR4 and FOXA2 (left part) and GAPDH, MYOD1 and HOXD11 promoter (right
part) at endo_d4 in untreated and doxy-treated cells. Results represent the mean of three independent experiments ±SEM. * p < 0.05. C.
Histone modification levels of H3K27me3 at ALBUMIN and AAT (left part) and GAPDH, MYOD1 and HOXD11 promoter (right part) at
FH_d16 in untreated and doxy-treated cells. Results represent the mean of three independent experiments ±SEM. * p < 0.05, ** p < 0.01.
https://doi.org/10.1371/journal.pone.0186884.g004
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Fig 5. miRNA and EZH2 mRNA degradation. A. Relative gene expression (to GAPDH) of endogenous and exogenous EZH2 (Total
EZH2) daily during the transition from endoderm stage (day 4, endo_d4) to hepatoblast progenitor (day 8, HP_d8) in untreated (-) and
EZH2 doxy induced cells (+). Data as mean ± SEM of n = 3 IEs. B. Relative expression of miR-101, miR-138, miR-214 and miR-124
during hepatocytes differentiation from hPSC-iEZH2 cell line doxy induced the first 8 days of differentiation. Relative gene expression to
U6. Data as mean ± SEM of n = 3 IEs. C. Name, functions and reference papers of the miRNAs analyzed.
https://doi.org/10.1371/journal.pone.0186884.g005
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enhanced commitment to early-established lineage decisions under the direction of EZH2
expression.
To unravel to role of EZH2 during hepatocyte commitment, we assessed EZH2 transcript
and protein expression during hepatocyte differentiation from hPSCs. EZH2 protein levels
increased significantly on day 4 and day 8, but decreased to nearly zero on day 16 of differentia-
tion. To determine if differentiation would be enhanced if levels of EZH2 were further induced
during the initial stages of differentiation, we inducibly overexpressed EZH2, by incorporating a
doxy inducible EZH2 cassette by RMCE in the AAVS1 locus of hPSCs created in our lab [26].
When EZH2 expression was induced between day 0 and day 8 of the hepatocyte differentiation
protocol, we demonstrated not only a more homogenous endoderm population on day 4, but
also improved hepatoblast maturation on day 16. However, we demonstrated that doxy-medi-
ated induction of EZH2 is associated with a significant increase in overall H3K27me3 of hPSC
progeny on day 4, day 8 and day 16. In line with our previous study, high levels of H3K27me3
staining persisted until day 16, and this despite the further commitment of endoderm cells to
hepatoblasts [24]. Interestingly, we demonstrated that ALBUMIN and AAT hepatocyte marker
genes showed less H3K27me3 at the end of the differentiation. We hypothesize that EZH2 over-
expression might induce not- hepatocyte specific genes to retain H3K27me3 in favor of the
expression of hepatocyte specific genes expression.
The decrease in EZH2 expression from day 4 onwards despite continuous administration of
doxy till day 8 was surprising. We previously described that inducible transgene expression
from AAVS1 was inhibited during hepatic differentiation through an unknown mechanism
compatible with TRE-silencing triggered by TRE inactivity. However, inducible expression
was robust through the whole differentiation process when doxy was applied starting from
day-2 or day 4 [26]. As expression of EZH2 was induced on day 0, the AAVS1-mediated inhibi-
tion is highly unlikely to explain the down-regulation of EZH2 from day 4 onwards. This loss,
therefore suggested post-transcriptional modulation of EZH2 expression from day 4 onwards
in the presence of doxycycline.
miRNAs are small non-coding RNAs that regulate the expression of more than 60% of pro-
tein coding genes in the human genome [44] by silencing target genes either via binding in a
sequence specific manner messenger RNAs and cleaving them, or by inhibiting their transla-
tion [45]. miRNAs are known to regulate lineage-specific differentiation [46–51]. Expression
of EZH2 can be modulated by direct binding of miRNAs, including miR-101, miR-138 and
miR-214, to EZH2 [33,34,52]. In line with this, we observed that that these miRNAs as well
as an additional 8 miRNAs predicted to bind EZH2, were significantly induced from day 4
onwards, which coincides with the progressive decrease of EZH2 mRNA and protein. There-
fore, the loss of EZH2 from day 4 onwards despite transgenic overexpression until day 8, is
likely due to miRNA mediated degradation, although further studies will be needed to demon-
strate if miRNAs are the only responsible for this observation.
Conclusion
In conclusion, we demonstrate that overexpression of EZH2 early during the differentiation of
hPSCs to hepatoblasts improved definitive endoderm formation and subsequent HLC genera-
tion. Surprisingly, despite doxy-mediated overexpression of EZH2 until day 8 of differentia-
tion, transcript and protein levels of EHZ2 decreased precipitously from day 4 onwards. This
was concomitant with increased levels of miRNAs known/predicted to inhibit EZH2 expres-
sion, which might be responsible for post-transcriptional regulation of EZH2 from day 4
onwards. In addition, despite the loss of EZH2 expression, overall H3K27me3 levels remained
high until day 16 of differentiation. In conclusion, we demonstrate that EZH2, of which the
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expression is tightly post-transcriptionally regulated, has a role in endoderm formation and
enhanced levels of the Polycomb gene leads to improved hepatocyte differentiation.
Supporting information
S1 Fig. Polycomb group of genes expression. Relative gene expression (to GAPDH) of Poly-
comb group of genes (EZH2, EZH1, SUZ12, EED, RING1B and BMI1) in hPSCs, endoderm
stage (day 4, endo), hepatoblast progenitor (day 8, HP) and fetal hepatocytes (day16, FH) of
the hepatocytes differentiation. Data as mean ± SEM of n 3 IEs.  p< 0.05,  p< 0.01.
(TIFF)
S2 Fig. Characterization of hPS-iEZH2 cell line. A. Relative gene expression (to GAPDH) of
pluripotent marker genes (OCT4 and NANOG) in endo_d4 and HP_d8 untreated (-) and
EZH2 doxy induced cells (+). Data as mean ± SEM. B. Relative gene expression of both endog-
enous and exogenous EZH2 (Total EZH2;  same analysis as in Fig 3A) and EZH1 at endo_d4,
HP_d8 and FH_d16 in untreated (-) and EZH2 doxy induced cells (+). Relative gene expres-
sion to GAPDH. Data as mean ± SEM. C. Relative gene expression of RING1b at endo_d4,
HP_d8 and FH_d16 in untreated (-) and EZH2 doxy induced cells (+). Relative gene expres-
sion to GAPDH. Data as mean ± SEM.
(TIFF)
S3 Fig. Hepatocytes markers expression. A. Relative gene expression (to GAPDH) of fetal
(CKIT,CYP3A7 and CYP1A2) and hepatic marker genes (GSTA1, APOA1,NTCP, SRBI, MRP2,
HNF3G, PEPCK, PXR, CYP2A6 and CYP2C9) and TFs (CEBPB, P300 and PROX1) in HP_d8
and FH_d16 untreated (-) and EZH2 doxy induced cells (+). Data as mean ± SEM; protocol of
differentiation and EZH2 induction as in Fig 3A. B. Relative gene expression (to GAPDH) of
pancreatic genes in HP_d8 and FH_d16 untreated (-) and EZH2 induced cells (+). Data as
mean ± SEM.
(TIFF)
S4 Fig. miRNAs analysis. A. The first 27 predicted miRNAs scored out of miRDB online data-
base (http://mirdb.org/miRDB/) targeted EZH2 mRNA. B. Relative expression of 8 micro-
RNAs (miR-31, miR-98, miR-125, miR-139, miR-181a, miR-181b, miR-200b and miR-217)
during hepatocytes differentiation from hPSC-iEZH2 cell line doxy induced the first 8 days of
differentiation. Relative gene expression to U6. Data as mean ± SEM of n = 3 IEs.
(TIFF)
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